IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.2799
-0.0050 (-1.76%)
Oct 9, 2026, 4:00 PM EDT - Market closed
IGC Pharma Employees
IGC Pharma had 70 employees as of March 31, 2025. The number of employees increased by 3 or 4.48% compared to the previous year. That makes IGC Pharma the 33,380th largest employer in the world and 4,385th in the United States.
Employees
70
Change (1Y)
3
Growth (1Y)
4.48%
Revenue / Employee
$15,800
Profits / Employee
-$92,086
Market Cap
28.94M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2025 | 70 | 3 | 4.48% | 70 | 0 |
| Mar 31, 2024 | 67 | 6 | 9.84% | 67 | 0 |
| Mar 31, 2023 | 61 | 9 | 17.31% | 61 | 0 |
| Mar 31, 2022 | 52 | 2 | 4.00% | 52 | 0 |
| Mar 31, 2021 | 50 | 0 | - | 50 | 0 |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| Seres Therapeutics | 66 |
| Evaxion | 46 |
| BeyondSpring | 44 |
| NextCure | 40 |
| Quince Therapeutics | 38 |
| ABVC BioPharma | 19 |
| Context Therapeutics | 15 |
IGC News
- 12 days ago - IGC Pharma completes enrollment in Phase 2 CALMA trial - TheFly
- 12 days ago - IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026 - Accesswire
- 7 weeks ago - IGC Pharma reports Q2 EPS (3c) vs. (2c) last year - TheFly
- 7 weeks ago - IGC Pharma sees cash runway for 12 months from quarterly report filing date - TheFly
- 7 weeks ago - IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure - Accesswire
- 1 month ago - IGC Pharma Quarterly report: Q2 2026 - Filings
- 1 month ago - IGC Pharma Earnings release: Q2 2026 - Filings
- 2 months ago - IGC Pharma strengthens regulatory readiness of Phase 2 CALMA trial - TheFly